SEC Form 4 · accession 0000950138-17-000021
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gary M. Phillips
Officer — Exec. VP & Chief Strategy Ofcr
Period of report
Jan 2, 2017
Accepted (ET)
Jan 4, 2017 · 9:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jan 2, 2017 | A | 6,732 | $0.00 | A | 18,309 | D | |
| Ordinary Shares | Jan 2, 2017 | F | 3,073 | $49.82 | D | 15,236 | D | |
| Ordinary SharesF2 | Jan 3, 2017 | A | 7,733 | $0.00 | A | 22,969 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Share Options (Right to Buy)F3 | $51.73 | Jan 3, 2017 | A | 43,441 | A | Jan 3, 2018 | Jan 3, 2027 | Ordinary Shares | 43,441 | 43,441 | D |
| Employee Share Options (Right to Buy)F4 | $51.73 | Jan 3, 2017 | A | 36,925 | A | Jan 3, 2021 | Jan 3, 2027 | Ordinary Shares | 36,925 | 36,925 | D |
Explanation of responses
- F1Vesting of performance share award granted on January 2, 2014.
- F2Represents restricted stock units that vest in four equal annual installments beginning January 3, 2018.
- F3The options vest in four equal annual installments beginning January 3, 2018.
- F4The options vest in their entirety on January 3, 2021.